Minapharm PharmaceuticalsCAI:MIPH -0.27%41 PB Ratio is 1.37 as of Jul. 13, 2026, which is 85% above its 10-year median of 0.74. GuruFocus rates CAI:MIPH with a GF Score™ of 41/100 and a GF Value™ of E£362.31 (Significantly Overvalued). The stock has 10 warning signs investors should review. Among 924 Drug Manufacturers companies, Minapharm Pharmaceuticals ranks better than 63.96% on this metric.
Minapharm Pharmaceuticals stock PB Ratio (=1.38) is close to 5-year high of 1.38.
The historical rank and industry rank for Minapharm Pharmaceuticals's PB Ratio or its related term are showing as below:
CAI:MIPH'
s PB Ratio Range Over the Past 10 Years
Min: 0.45 Med: 0.74 Max: 1.38
Current: 1.38
During the past 5 years, Minapharm Pharmaceuticals's highest PB Ratio was 1.38. The lowest was 0.45. And the median was 0.74.
CAI:MIPH's PB Ratio is ranked better than 63.96% of 924
companies
in the Drug Manufacturers industry
Industry Median: 1.91
vs CAI:MIPH: 1.38
During the past 12 months, Minapharm Pharmaceuticals's average Book Value Per Share Growth Rate was 45.10% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 28.30% per year.
During the past 5 years, the highest 3-Year average Book Value Per Share Growth Rate of Minapharm Pharmaceuticals was 31.80% per year. The lowest was 28.30% per year. And the median was 30.05% per year.
Back to Basics: PB Ratio
Minapharm Pharmaceuticals (CAI:MIPH) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Minapharm Pharmaceuticals PB Ratio Related Terms
Minapharm Pharmaceuticals PB Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Minapharm Pharmaceuticals's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Minapharm Pharmaceuticals PB Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Minapharm Pharmaceuticals's PB Ratio distribution charts can be found below:
* The bar in red indicates where Minapharm Pharmaceuticals's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Minapharm Pharmaceuticals (CAI:MIPH) has a PB Ratio of 1.37 as of Jul. 13, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Minapharm Pharmaceuticals and its competitors. This is 85% above median its historical median of 0.74. Over the past decade, Minapharm Pharmaceuticals' PB Ratio has ranged from 0.45 to 1.38. According to the industry distribution chart, Minapharm Pharmaceuticals ranks #333 out of 924 companies in the Drug Manufacturers industry, placing it in the top 36%.
Is Minapharm Pharmaceuticals' PB Ratio too high?
Minapharm Pharmaceuticals' current PB Ratio of 1.37 is 85% above median its 10-year median of 0.74. Over the past 10 years, this metric has ranged from a low of 0.45 to a high of 1.38. The Drug Manufacturers industry median PB Ratio is 1.91. Minapharm Pharmaceuticals' value of 1.37 is 28.3% below this industry median. Based on the distribution chart, Minapharm Pharmaceuticals ranks #333 out of 924 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Minapharm Pharmaceuticals has a GF Score™ of 41/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Minapharm Pharmaceuticals' PB Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Minapharm Pharmaceuticals ranks #333 out of 924 companies for PB Ratio. This puts Minapharm Pharmaceuticals in the upper half of its industry. The industry median PB Ratio is 1.91. Minapharm Pharmaceuticals' value of 1.37 is 28.3% below this benchmark. Historically, Minapharm Pharmaceuticals' own PB Ratio has ranged from 0.45 to 1.38 over the past decade. While the company's 10-year median is 0.74 vs. the industry median of 1.91, Minapharm Pharmaceuticals has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Drug Manufacturers company?
The median PB Ratio among Drug Manufacturers companies is 1.91, based on 924 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Minapharm Pharmaceuticals's current PB Ratio of 1.37 is 28.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Minapharm Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median PB Ratio is 1.91 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Minapharm Pharmaceuticals's current PB Ratio is 1.37, which is 85% above median its own 10-year median of 0.74. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Minapharm Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Minapharm Pharmaceuticals (CAI:MIPH) is currently considered Significantly Overvalued. The stock's GF Value™ is E£362.31, compared to a current price of E£698.08 — trading 92.7% above its estimated fair value. The current PB Ratio is 1.37, which is 85% above median its 10-year median of 0.74 and 28.3% below the Drug Manufacturers industry median of 1.91. Minapharm Pharmaceuticals' overall GF Score™ is 41/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Minapharm Pharmaceuticals (CAI:MIPH), the current PB Ratio is 1.37 as of Jul. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Minapharm Pharmaceuticals (CAI:MIPH) Overvalued in 2026?
Based on GuruFocus' analysis, Minapharm Pharmaceuticals stock appears to be overvalued.
The current stock price of E£698.08 is trading 92.7% above its estimated GF Value™ of E£362.31.
GuruFocus considers Minapharm Pharmaceuticals to be Significantly Overvalued.
Key valuation signals for CAI:MIPH:
PB Ratio: 1.37 (85% above median its 10-year median of 0.74)
GF Value™: E£362.31 vs. price of E£698.08 (92.7% above fair value)
Industry Position: 28.3% below the Drug Manufacturers median (#333 of 924)
No single metric tells the full story. See the CAI:MIPH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Minapharm Pharmaceuticals is a company whose purpose is to produce medicines and chemicals. medical supplies. cosmetics, veterinary medicines, dental supplies, and the production of dietary supplements and herbal medicines. It produces drugs for many segments such as biogenetics, orthopedic, ophthalmology, miscellaneous, dermatology, gastroenterology, cardiology, and uro-gynaecology lines.
41GF Score
Get the complete analysis for CAI:MIPH
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CAI:MIPH has been successfully added to your 
